EAST SETAUKET. N. Y.. Nov. 29 /PRNewswire-FirstCall/ -- John S. Kovach. M. D.. Chair. Board of Directors and CEO of Lixte Biotechnology Holdings. Inc announces the appointment of Stephen K. Carter. M. D to the company's come in of Directors.
Dr. Carter is a highly experienced leader and administrator in cancer therapeutics and cancer drug development. For 13 years he was associated with Bristol-Meyers Co and Bristol-Meyers Squibb. Co holding successively the positions of Senior Vice President. Anti-Cancer Research; President. Division of Pharmaceutical investigate and Development and ultimately Senior Vice President. Worldwide Clinical Research and Development. Pharmaceutical Research initiate. Most recently Dr. Carter was Senior Vice President of Clinical and Regulatory Affairs at Sugen. Inc. after serving as Senior Vice President for Research and Development at Boehringer Ingelheim Pharmaceuticals. Inc. Dr. Carter held leadership roles in academia and government including Deputy Director. Division of Cancer Treatment. National Cancer initiate and Director. Northern California Cancer Program.
Dr. Carter is currently a director on the boards of; Cytogen Corporation. Alfacell Corporation. Tapestry Pharmaceuticals. Inc.. Callisto Pharmaceuticals. Inc.. Vion Pharmaceuticals. Inc and Celator.
"We are extremely pleased that Dr. Carter has joined our board of directors. Steve has had an exceptional go and is internationally recognized for his expertise in cancer medicate development. In addition to his depth of knowledge and undergo in applied cancer research and the pharmaceutical industry he has served on the boards of various publicly held companies. He brings Lixte a wealth of experience in oversight and governance. We very much look forward to working with him" stated Dr. Kovach.
Lixte Biotechnology Holdings. Inc. (Lixte) is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005 the affiliate develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year based on the discovery of a new biomarker for brain cancers by collaborators at NIH the company is developing new drugs for the treatment of glioblastoma multiforme (GMB) the most common and most aggressive type of primary hit cancer in adults and to a much lesser extent in children.
GBM occurs annually in 20,000 to 25,000 adults in the United States and in a comparable be of individuals in Europe. At present there is no curative treatment known for this disease. Standard treatment involves surgery radiation and the use of one or more chemotherapeutic agents at the time of initial treatment. At change state which occurs in essentially all patients the show standard treatment is a drug. Temozolomide that is associated with a modest increase in life span measured in months. Thus there is an urgent be for more effective treatments for this disease.
Over the next year as part of its collaboration with NIH the company ordain complete the determination of the effectiveness of a bring about compound from each of two different classes of drugs developed by Lixte that are active against GBM in the test furnish. The next step will be characterization of the anti-tumor activity of these drugs in an animal copy of human GBM and description of their pharmacologic behavior and metabolism in animals. Subsequently the toxicity profiles of active drugs will be determined in pre- clinical toxicology studies. Should the results of the foregoing tests and studies be successful we hope to conform to all requirements of the FDA for approval of at least one lead increase for evaluation in Phase I trials in late 2008 or early 2009. Lixte will also evaluate the anti-cancer activity of its new compounds against two life-threatening cancers of children neuroblastoma and medulloblastoma and against several common cancers of adults in addition to GBM.
NINDS (www ninds nih gov) is a component of the National Institutes of Health (NIH) and is the nation's primary supporter of biomedical research on the brain and nervous system.
The National Institutes of Health (NIH) - The Nation's Medical investigate Agency - includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic clinical and translational medical research and it investigates the causes treatments and cures for both common and rare diseases. For more information about NIH and its programs tour www nih gov.
This announcement contains certain forward-looking statements within the meaning of divide 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example statements regarding the Company's financial lay business strategy and other plans and objectives for future operations and assumptions and predictions about future product bespeak give manufacturing costs marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "accept," "estimate," "potential(ly)," "act," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable based on information available to it on the date hereof but the affiliate cannot give assurances that these assumptions and expectations will be to have been change by reversal or that the affiliate ordain act any challenge that the Company may presently be planning. However these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or alter to such differences include but are not limited to regulatory policies available cash investigate results competition from other similar businesses and merchandise and command economic factors. This discussion should be construe in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of the Quarterly Report on create 10-QSB for the quarter ending June 30. 2007.[ADVERTHERE]Related article:
http://www.biospace.com/news_story.aspx?StoryID=78883&full=1
comments | Add comment | Report as Spam
|
